BerandaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$4,20
Rentang hari
$4,05 - $4,21
Rentang tahun
$3,36 - $5,44
Kapitalisasi pasar
150,91 jt USD
Volume Rata-Rata
4,21 rb
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (CHF) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 3,60 jt | -18,25% |
Penghasilan bersih | -11,84 jt | 27,85% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,33 | 32,65% |
EBITDA | -11,40 jt | 18,54% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 104,52 jt | -27,22% |
Total aset | 112,15 jt | -27,27% |
Total liabilitas | 16,62 jt | 7,70% |
Total ekuitas | 95,53 jt | — |
Saham yang beredar | 37,40 jt | — |
Harga terhadap nilai buku | 1,65 | — |
Tingkat pengembalian aset | -25,23% | — |
Tingkat pengembalian modal | -29,02% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -11,84 jt | 27,85% |
Kas dari operasi | -9,93 jt | 25,27% |
Kas dari investasi | 10,66 jt | -25,01% |
Kas dari pembiayaan | -304,00 rb | -1,00% |
Perubahan kas bersih | 384,00 rb | 481,82% |
Arus kas bebas | -5,40 jt | 33,24% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
153
